+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Growth Hormone Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Growth Hormone Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

RET (Ret Proto-Oncogene) Protein Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
Diabetic Neuropathic Pain- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Neuropathic Pain- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Nephropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Diabetic Foot Ulcers - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Foot Ulcers - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Fabry Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Fabry Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Insulin Resistance - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Resistance - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2025 - Product Thumbnail Image

Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Secondary Hyperparathyroidism - Pipeline Insight, 2025 - Product Thumbnail Image

Secondary Hyperparathyroidism - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Porphyria - Pipeline Insight, 2025 - Product Thumbnail Image

Porphyria - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 65 Pages
  • Global
From
Pompe Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Pompe Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Exocrine Pancreatic Insufficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Exocrine Pancreatic Insufficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Idiopathic Short Stature - Pipeline Insight, 2025 - Product Thumbnail Image

Idiopathic Short Stature - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Glucokinase Activators - Pipeline Insight, 2025 - Product Thumbnail Image

Glucokinase Activators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more